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Purpose: Direct comparison of transposed arteriovenous fistulas (tAVF) and arteriovenous grafts (AVG) has been
hampered by inherent differences in patient characteristics between tAVF and AVG groups. In this study, using matching
to control patient variables, we evaluated our outcomes with upper arm tAVF and upper arm prosthetic AVG.
Methods: A retrospective review of all newly created upper arm tAVF and AVGwas performed. One hundred ninety upper
arm tAVF were group matched for age, gender, race, diabetes, and history of previous failed access with 168 AVG chosen
from a pool of 476 concurrently performed AVG procedures. Complication, patency, and intervention rates were
compared using multivariate analysis.
Results:Mean follow up for our cohort was 29.1 months. Transposed fistulae consisted of 119 basilic vein and 71 cephalic
vein transpositions, which were found to have similar demographic parameters, complication rates, and patency rates.
There were no differences in 30 day mortality, 24 hour thrombosis, bleeding requiring exploration, or ischemic steal
requiring intervention between the tAVF and AVG groups. More AVG developed infection requiring operative
exploration than tAVF (7.9% vs 1.6%, respectively. P  .004). Primary patency for tAVF was higher than for AVG: 48%
vs 14% at five years (P< .0001). Secondary patency rate for tAVF was also higher than for AVG: 57% vs 19% at five years
(P < .0001). Nine percent of tAVF compared with 53% of AVG required one or more surgical and/or percutaneous
revisions to maintain secondary patency (P < .0001). Multivariate analysis revealed that utilization of a tAVF was
associated with a reduced risk of primary (Hazard Ratio [HR] 0.47, 95% Confidence Interval [CI] 0.35-0.64, P< .0001)
and secondary failure (HR 0.59, 95% CI 0.42-0.81, P  .0001).
Conclusions: Transposed arteriovenous fistulas have significantly higher primary and secondary patency rates, require
fewer revisions, and are less likely to develop a significant infection than AVG. This study supports the contention that
as long as a patient is a candidate for a tAVF based on anatomic criteria, a tAVF should be considered before an AVG.
(J Vasc Surg 2009;50:1405-11.)When permanent hemodialysis access is needed place-
ment of the radiocephalic arteriovenous fistula (AVF) is
usually considered first.1-4 The forearm cephalic veins,
however, are often not suitable for AVF creation due to
small diameter, thrombosis, or stenosis caused by repeated
venipuncture. Although an antecubital brachial-cephalic
AVF is recommended when a wrist AVF is not feasible,4
presence of venipuncture related cephalic vein stenosis and
thrombosis at the antecubital fossa may, likewise, hinder
the construction of this type of fistula.1 According to the
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doi:10.1016/j.jvs.2009.07.090Quality Initiative (KDOQI) Vascular Access Guidelines, if
construction of a wrist or elbow AVF is not possible, a
brachial basilic vein AVF or basilic vein transposition (BVT)
is preferred; prosthetic arteriovenous graft (AVG), how-
ever, may also be acceptable.4
Transposed upper arm arteriovenous fistulas (tAVF)
such as BVT and cephalic vein transposition (CVT) have
been described in patients who are not candidates for
forearm native AVF.5-7 Although there are a number of
reports describing excellent patency of BVT, 7-12 there are
some studies that report equivocal results.13,14 A recent
report of 185 patients demonstrated relatively low, equiv-
alent patencies between transposed brachiobasilic AVF and
prosthetic brachioaxillary access grafts.15
Outcomes of studies comparing tAVF and AVG are
often difficult to interpret due to differences in patient
characteristics, such as age, gender, and race that exist
between these two groups.11,16-19 Older age, female gen-
der, and African-American (AA) race have been found to be
independent risk factors associated with decreased AVF
prevalence1,20,21 andmay affect outcomes. Previous studies
have controlled for these systematic differences in back-
ground characteristics between the two groups using re-
gression techniques (eg, Cox regression, linear, or logistic
regressions); however, these methods of controlling are
efficient as long as model assumptions are correct. In order
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AVG, we chose to control for the confounding differences
that typically exist in patient populations undergoing these
procedures by comparing case matched cohorts undergo-
ing tAVF or AVG placement.
METHODS
We retrospectively evaluated all upper arm tAVF and
upper arm, brachial artery-axillary vein, straight configura-
tion, prosthetic AVG performed at Cedars-Sinai Medical
Center in Los Angeles, California between January 1998
and September 2004. The fistula group consisted of upper
arm BVT and CVT procedures and has been described
previously.7 This tAVF group included patients who had
previous access construction in the ipsilateral as well as the
contralateral upper extremity.
The tAVF group was matched for age, gender, race,
diabetes, and history of previous failed access with a group
of AVG chosen from a pool of concurrently performed
AVG procedures. These chosen factors have been found to
be associated with outcomes and thus likely confound the
fistula and graft comparison.7,11,16-19 Only primary upper
arm AVG were included for evaluation; there were no
previous access procedures performed in the ipsilateral up-
per extremity of the AVG patients.
Office, hospital, and electronic charts were reviewed
after Institutional Review Board exemption status was
granted. Co-morbid conditions were noted and graded
according to the recommended reporting standards.22
All patients underwent preoperative noninvasive vascu-
lar evaluation that included brachial pressures and wave-
forms, Allen’s test, and brachial/radial artery diameter
measurements. Vein mapping was routinely performed to
outline and define the size and quality of basilic and ce-
phalic veins.7 If the vein in question had a stenosis, and the
patient had another vein that was suitable for construction
of AVF, we preferentially used the optimal vein.
In our practice, we attempted to first place a wrist
radiocephalic fistula if anatomically favorable. From there,
we moved to a simple brachiocephalic fistula at the antecu-
bital fossa. If this was not feasible, we placed either an upper
arm AVG or an upper arm tAVF. The forearm transposed
fistula or loop forearm grafts were rarely used and were not
included in this series.
The decision to construct an upper arm tAVF was
based, in general, on the presence of adequate arterial
inflow into the arm, upper arm vein diameter2.5 mm and
absence of suitable forearm site for an autogenous fistula. If
upper arm cephalic vein was judged adequate on duplex
evaluation and superficial on tourniquet-aided examination
by the surgeon, an antecubital non-transposed brachioce-
phalic fistula was constructed. Otherwise, either an upper
arm BVT or CVT was placed. The larger of the two upper
arm veins, as measured by duplex, was used preferentially.
We were liberal to transpose the cephalic vein if it was not
easily palpable on tourniquet-assisted physical examination.
Patients who were judged not to be candidates for a native
AVF underwent placement of an upper arm, straight con-figuration, 6 mm polytetrafluoroethylene (PTFE) AVG
(WL Gore and Associates Inc, Phoenix, Arizona, USA and
Bard Inc, Tempe, Arizona, USA). No looped arm, or
tapered AVGwere utilized. Ultimately, the decision of type
of access was determined by surgeon preference.
Operative details are described in Appendix I (online
only).
Perioperative and postoperative complications were
followed and recorded by the operative surgeon. Compli-
cations were graded according to the recommended stan-
dards for reports dealing with arteriovenous hemodialysis
access procedures. The complications followed were: grade
2 wound infection (requiring operative exploration or re-
moval of access), grade 3 (severe) steal (requiring manda-
tory intervention), grade 3 postoperative hemorrhage (ne-
cessitating return to the operating room) and fistula
thrombosis within 24 hours.22 Grade 3 steal was treated
either with fistula banding or the Distal Revascularization
Interval Ligation procedure. Thirty-day mortality rate was
calculated.
A follow up visit with the vascular surgeon was sched-
uled during the first month after discharge for suture
removal and at that time fistula patency was assessed by
physical examination. Transposed AVF were allowed to
mature for a minimum of eight weeks and the decision
when to use the access for the first time was made either by
the attending surgeon or nephrologist. Grafts were typi-
cally accessed for dialysis 10 to 14 days after implantation.
No routine surveillance was performed. Non-invasive
imaging was used in the initial evaluation of a malfunction-
ing access. A fistulagram was performed only when symp-
tomatic fistula or graft stenosis were suspected. This was
done when intra-access flow was less than 600 cc/min and
static or dynamic venous pressures were high. In addition,
elevated access recirculation also prompted referral for fis-
tulography. Invasive imaging was not routinely performed
for asymptomatic stenosis.
When a prosthetic access occluded, it was reopened
using either mechanical or surgical thrombectomy. If me-
chanical thrombectomy was used, balloon angioplasty of
any identified stenosis was attempted. If surgical thrombec-
tomy was used, surgical repair of the underlying lesion was
attempted. Occluded tAVF were either abandoned or re-
opened using mechanical thrombectomy. In the latter case,
percutaneous angioplasty or surgical revision was at-
tempted.
For each tAVF record amatched AVG record (matched
for age, gender, race, diabetes, and history of previous
failed access) was sought from a pool of 476 concurrently
performed AVG procedures. For matching, age was opera-
tionalized as a categorical variable with categories: (1) less
than 40, (2) between 40 and 60, (3) between 60 and 80,
and (4) greater than 80.
Statistical analysis was performed using the Statistical
Analysis System (SAS Institute Inc., Cary, NC). Summary
results for were presented as mean  standard deviation
continuous variables and as frequency (percent) for cate-
gorical variables. Two-group comparisons were assessed by
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test, as appropriate of continuous variables and by chi-
squared test or Fisher’s exact test for categorical variables.
Fistula and graft patency and limb abandonment rates at
each time point were calculated by the life table method as
outlined by the Society of Vascular Surgery Ad Hoc Com-
mittee on Reporting Standards.22 Survival differences were
tested with the Log rank test.
Primary patency was defined as time of access place-
ment until first thrombosis or any intervention designed to
maintain patency.22 Follow-up for primary patency rate
calculations ended when the graft was confirmed to require
intervention, thrombosed, or last known to be patent
(whichever was shorter). Placement of a dialysis catheter in
a patient with a presumably functioning graft, death, or
kidney transplantation was an additional endpoint for ter-
mination of patency. Secondary patency was defined as
the interval from the time of access placement until
access abandonment.22 Secondary patency rate calcula-
tions ended when the patient had a new surgical dialysis
access placed. The placement of a new dialysis access was
used as a surrogate for access abandonment. Although
placement of a new dialysis access did not occur at the exact
point of access abandonment, placement of a new dialysis
access generally occurred within one to two months of
access abandonment.
Bivariate analysis was performed.Multivariate Cox pro-
portional hazard models were then evaluated to assess
association of variables analyzed in the bivariate analysis and
type of surgery (AVG vs. tAVF) on the hazard of primary or
secondary access failure while controlling for other inde-
pendent predictor variables. To search for a final model we
used the stepwise selection.
RESULTS
During the 6.5 year study period, 190 upper arm tAVF
were constructed in 190 patients. There were 119 BVT and
71 CVT procedures. Four hundred seventy six concur-
rently performed primary upper arm AVG were identified.
Out of the AVG cohort, 168 AVG performed in 168
patients were matched with the tAVF cohort with respect
to age, gender, race, diabetes, and history of previous failed
access. There was no significant difference in the age,
gender, race, history of previous access and diabetes be-
tween the tAVF and AVG cohorts (Table I).
There was no significant difference in the thirty day
mortality, 24 hour thrombosis, grade 3 postoperative hem-
orrhage or grade 3 steal between the two groups (Table II).
There were significantly more grade 2 infections requiring
operative exploration in the AVG group; 7.9% vs 1.6% (P
.004).
Mean follow up for the tAVF and AVG cohorts were
27.1 and 31.4 months, respectively (P  .071). The pri-
mary patency at one and five years for the tAVF cohort was
65% and 48%, and for the AVG cohort was 42% and 14%,
(P .001) (Fig 1, Appendix 2, online only). The secondary
patency at one and five years for the tAVF cohort was 72%and 57% and for the AVG cohort was 67% and 19% (P 
.001) (Fig 2, Appendix 3, online only).
Four surgical and 22 endovascular revisions were re-
quired in the tAVF group to maintain secondary patency.
In the AVG group, 120 surgical and 127 endovascular
revisions were required to maintain secondary patency (P
.001). Among the tAVF procedures, 9% required one or
more revisions to maintain secondary patency, compared
with 53% in the AVG group (P  .001).
Bivariate analysis showed that history of previous upper
extremity access increased the risk of primary failure and
secondary failure (Tables III and IV). In bivariate analysis,
male gender decreased the risk of secondary failure (Table
IV). Multivariate analysis showed that presence of tAVF
decreased the risk for primary (Hazard Ratio [HR] .47,
95% Confidence Interval [CI] .35 to .64, P  .001) and
secondary failure (HR .57, 95% CI .41 to .78, P  .001).
History of previous access increased the risk of primary (HR
1.61, 95% CI 1.17 to 2.2, P  .003) and secondary failure
(HR 1.67, 95% CI 1.19 to 2.35, P  .003).
DISCUSSION
Long term hemodialysis access includes native AVF and
prosthetic AVG. In the mid 1990s, only 20% of patients in
the United States were dialyzing with native fistulas.23
Because of data illustrating superior patency of native AVF,
the National Kidney Foundation Kidney Disease Outcome
and Quality Initiative (KDOQI) recommended, among
other things, that native fistulas should be constructed in at
Table I. Patient characteristics according to access type
tAVF (%) AVG (%) P value
Age
40 26 (13.7) 16 (9.7) .356
(40,60) 51 (26.8) 36 (21.8)
(60,80) 79 (41.6) 78 (47.3)
80 34 (17.9) 35 (21.2)
Male gender 120 (63) 88 (53) .061
AA race 47 (25) 28 (29) .355
Diabetes (grade 1-3) 97 (51) 74 (45) .243
Previous UE access 37 (19) 45 (27) .082
AA, African-American; AVG, arteriovenous grafts; SD, standard deviation;
tAVF, transposed arteriovenous fistulas; UE, upper extremity.





(%) OR (95% CI)
P
value
30 day mortality 5 (2.6) 5 (3.0) 0.86 (0.25,3.04) .821
Infection (grade 2) 3 (1.6) 13 (7.9) 0.19 (0.05,3.04) .004
24 hour thrombosis 1 (0.5) 2 (1.2) 0.43 (0.04,480) .481
Bleeding (grade 3) 7 (3.7) 3 (1.8) 2.07 (0.53,8.12) .289
Steal (grade 3) 6 (3.2) 8 (4.9) 0.64 (0.22,1.88) .414
AVG, Arteriovenous grafts;OR, odds ratio; tAVF, transposed arteriovenous
fistulas.least 50% of permanent hemodialysis access procedures.3,4,24
F and
VF an
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ages use of native fistulas by providing physicians with an
algorithm designed to optimize care of patients with end
stage renal disease (ESRD).24 Despite these recommenda-
tions, the prevalence of native arteriovenous fistula use was
Fig 1. Primary patency of tAV
Fig 2. Secondary patency of tAonly 36% in 2004.24Twenty to thirty years ago, patient selection for dialysis
was relatively stringent and most patients were young,
non-diabetic men whose veins were well suited for con-
struction of native arteriovenous fistula at the wrist. In
recent years, liberalization of selection criteria for dialysis in
AVG. AA, African-American.
d AVG. AA, African-American.the United States has led to inclusion of patients who are
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eral vascular disease, and less likely to have preserved fore-
arm veins. Increasing complexity of patients with ESRDhas
increasingly been associated with clinical scenarios where
wrist or simple antecubital fistula construction is not possi-
ble. Efforts to limit the use of prosthetic AVG in these
clinical settings led to increased utilization of tAVF for


















Caucasian 0.891 0.558 1.424 .6296
AA 1.261 0.764 2.079 .3641
Other 1
Age
40 1.134 0.644 1.998 .6623
(40,60) 1.174 0.734 1.879 .5035
(60,80) 1.335 0.874 2.041 .1817
80 1
Diabetes
No 1.077 0.807 1.438 .6151
Yes 1
Gender
Male 0.742 0.556 0.990 .0423
Female 1
Previous access
No 0.522 0.384 0.711 .0001
Yes 1




















Caucasian 1.392 0.763 2.540 .2804
AA 1.745 0.926 3.288 .0850
Other 1
Age
40 1.229 0.669 2.258 .5059
(40,60) 1.016 0.599 1.726 .9524
(60,80) 1.263 0.793 2.011 .3257
80 1
Diabetes
No 1.065 0.776 1.462 .6956
Yes 1
Gender
Male 0.702 0.511 0.963 .0281
Female 1
Previous access
No 0.519 0.371 0.725 .0001
Yes 1dialysis access.Both BVT and CVT have been used extensively and
have been shown to have similar patency rates.7 Despite
excellent outcomes found by some,7,10,11 others describe
relatively poor tAVF patency rates.13,25 These differences
mainly stem from variability in maturation rates of native
arteriovenous fistulas.26 Variable outcomes of tAVF has
resulted in continued utilization of AVG even when tAVF
construction was possible.7
There have been a number of studies that compared
outcomes of tAVF and AVG.7,11,16,27,28 Many of these
studies have been hampered by differences that exist be-
tween patients offered native fistulas and grafts.11,16-19 It
has been demonstrated that there are a variety of patient
factors that influence the prevalence of fistula creation.1
Female gender has been repeatedly shown to be a strong
predictor of AVG use.1,20,29,30 Similarly, a number of
studies have demonstrated that AVF are used less com-
monly in African-Americans.16,29 Increased age20,29 and
presence of diabetes20 have also been associated with de-
creased prevalence of fistula use. Furthermore, age,13,19,31
diabetes,1,10,32 female gender,1,33 and history of previous
failed dialysis access7,28,34 have been shown to predict
access failure. In order to limit the effect of these confound-
ing factors on outcomes, we performed case matching of
our tAVF and AVG groups to control for age, gender, race,
diabetes, and history of previous failed access and then used
multivariate regression techniques to assess outcome differ-
ences between the two procedures. Matching followed by
regression has been described to be superior to either
method alone.35
In our study, the tAVF cohort had a significantly higher
primary and secondary patency rates compared with the
AVG group. This finding is supported by some,11,27 but
not all series.16,28 A recent report from the United King-
dom directly compared BVT and brachioaxillary AVG in
two groups that were well matched for age, gender, ethnic-
ity, diabetes, and number of prior access procedures.15 The
authors found no significant differences in secondary pa-
tency between the two procedures. One potential explana-
tion for these findings is that the one year secondary pa-
tency of BVT in this series was only 56.4%, and thereby
significantly lower than our 72% tAVF secondary patency.
The patency of tAVF in our study is furthermore higher
than that of another recent series of tAVF where one-year
primary and secondary patency rates were 23% and 47%,
respectively.25
In addition to low primary patency rates, patients in the
AVG cohort required significantly more endovascular and
operative interventions to maintain secondary patency.
Other authors have also noted increased intervention rates
in patients who dialyze through prosthetic grafts.11,16,36,37
In a recent study, equivalent secondary patency of BVT and
brachial artery-axillary vein polyetherurethaneurea (Vectra,
Bard Inc, Tempe, Arizona, USA) grafts were reported.38
However, to achieve this, significantly more thrombectomy
and angioplasty procedures were performed in failing grafts
compared with BVT fistulas.
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more infections requiring removal of the access in the AVG
group. This is consistent with other reports.15,37,38 There
was no difference between the groups with respect to
bleeding requiring operative intervention or steal requiring
operative intervention.
In the multivariate analysis, the most significant factor
contributing to improved primary and secondary patency
was use of tAVF. History of previous failed dialysis access
was another factor that adversely influenced primary and
secondary patency. This finding has been demonstrated by
other authors28,34 and may be related to yet undefined
patient factors such as propensity to intimal hyperplasia.
Age, gender, and diabetes did not exert an effect on patency
in our or other series.15,38
We compared outcomes of tAVF and AVG in a group
of patients well matched for the demographic factors that
may have confound results of others. This case matching
strengthens the validity of our finding. Nevertheless, our
study is not without limitations. The retrospective nature of
our series allows for introduction of bias and confounding
variables that may affect our conclusions. For instance, the
exact reason behind the choice to perform a given opera-
tion was not known and therefore surgeon bias could not
be well controlled. There were likely anatomical differences
in these patients such as vein quality and diameter which
affected whether or not tAVF or AVG were chosen. In
addition, because the time that first dialysis was initiated
through the fistula was not available to us, true fistula
non-maturation rates are unknown. We do make the ob-
servation that at three and six months the primary patency
for the tAVF group was 88% and 76%, respectively. Our
practice pattern was such that those fistulas that failed to
mature after three to four months were referred for new
access placement. Therefore, an assumption can be made
that our fistula non-maturation rate was between 12% and
24%. Lastly, there may have been other factors that could
have been controlled to allow for a more precise compari-
son between groups.
In our case matched series, we found upper arm tAVF
to have significantly higher patency rates, lower interven-
tion rates, and lower serious infection rates than upper arm
brachial artery-axillary vein straight PTFE AVG. It is our
conclusion that if a patient is a candidate for an upper arm
tAVF based on anatomical criteria he should always be
offered that procedure in lieu of a prosthetic graft.
The authors thank Laura M. Dember, MD, for her
assistance in review of the manuscript.
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In the operating room, the majority of procedures were
performed under local anesthesia with sedation. For pa-
tients who did not tolerate local anesthesia, general anes-
thesia was required. The basilic or cephalic vein was ex-
posed and dissected from 1-2 cm distal to the antecubital
fossa to the proximal axilla or shoulder, respectively. All
branches were controlled with silk suture and the vein was
divided distally. The brachial artery was then exposed im-
mediately proximal to the antecubital fossa and the vein was
tunneled superficially to lie next to the brachial artery. In
most cephalic vein transposition (CVT) procedures, the
brachial artery was exposed through a separate, medial
antecubital incision. After administration of systemic or local
heparin, an end to side anastomosis was constructed betweenthe transposed vein and brachial artery. The use of systemic
heparin was based on surgeon preference. When systemic
heparin was given, it was always reversed with protamine.
For upper arm AVG procedures, the brachial artery and
axillary vein were exposed through distal and proximal
medial upper arm incisions, respectively. Venous and arte-
rial anastomoses were constructed in an end to side fashion.
If the outflow vein is stenotic or diseased, we will make
every effort to construct the anastomosis proximal to the
stenosis. On occasion, a duplicated brachial or axillary vein
may serve as a better outflow vessel. The majority of pa-
tients were discharged the same day. Patients who were felt
to require observation due to co-morbidities or other ex-
tenuating circumstances were admitted to the hospital and
were discharged on the first postoperative day.
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AVG 0 190 1.00000 . .
AVG 12 99 0.44295 0.36211 0.52061
AVG 24 54 0.27149 0.19599 0.35235
AVG 36 32 0.21116 0.13990 0.29239
AVG 48 21 0.17737 0.10774 0.26119
AVG 60 7 0.15008 0.07960 0.24141
tAVF 0 168 1.00000 . .
tAVF 12 50 0.65143 0.57585 0.71689
tAVF 24 25 0.57905 0.49814 0.65157
tAVF 36 15 0.52758 0.43917 0.60839
tAVF 48 8 0.50804 0.41477 0.59385
tAVF 60 4 0.47300 0.36329 0.57491
AVG, Arteriovenous grafts; SDF, survival distribution function; tAVF, transposed arteriovenous fistulas.











AVG 0 190 1.00000 . .
AVG 12 110 0.67832 0.59504 0.74812
AVG 24 59 0.41428 0.32535 0.50079
AVG 36 34 0.28219 0.19794 0.37225
AVG 48 22 0.24994 0.16677 0.34187
AVG 60 8 0.19732 0.11233 0.29978
tAVF 0 165 1.00000 . .
tAVF 12 82 0.71920 0.64618 0.77973
tAVF 24 38 0.63884 0.55795 0.70884
tAVF 36 20 0.58615 0.49601 0.66567
tAVF 48 13 0.56559 0.46939 0.65089
tAVF 60 4 0.56559 0.46939 0.65089
AVG, Arteriovenous grafts; SDF, survival distribution function; tAVF, transposed arteriovenous fistulas.
